Crossmark

Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis

Crossref DOI link: https://doi.org/10.1186/s12879-019-3975-6

Published Online: 2019-05-30

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Snedecor, Sonya J.

Radford, Matthew

Kratochvil, David

Grove, Richard

Punekar, Yogesh S. https://orcid.org/0000-0002-7531-1319
Funding

Funding for this research was provided by:

ViiV Healthcare

GlaxoSmithKline
License Information

Text and Data Mining valid from 2019-05-30

Version of Record valid from 2019-05-30
More Information

Article History

Received: 18 January 2019

Accepted: 11 April 2019

First Online: 30 May 2019

Ethics approval and consent to participate

: Ethics approval and patient consent were not required because this study is a meta-analysis based on published studies.

: All authors have given their consent to publishing this work.

: SJS and DK are employees of Pharmerit International, and paid consultants to ViiV Healthcare and GlaxoSmithKline. Study conduct and data analysis were performed by Pharmerit International and funded by ViiV Healthcare and GlaxoSmithKline. No funding was provided to Pharmerit International for manuscript development. RG is an employee of GlaxoSmithKline. MR and YSP are employees of ViiV Healthcare. RG, MR, and YSP hold stocks and shares in GlaxoSmithKline as part of their employment.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below